BPC-157 vs Semaglutide
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
BPC-157GLP-1 / Weight Loss Agonists
Semaglutide- Summary
- BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
- Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
- Half-Life
- 4–6 hours
- ~7 days
- Admin Route
- SubQ, IM, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200–500 mcg
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- Frequency
- Once daily
- Once weekly, subcutaneous
- Key Benefits
- Accelerates wound healing and tissue repair
- Reduces inflammation throughout the body
- Protects and heals the gastrointestinal tract
- Supports tendon and ligament healing
- Promotes bone and joint health
- May protect organs from toxins and injury
- Supports gut-brain axis function
- Counteracts NSAID-induced gut damage
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
- Side Effects
- Injection site discomfort
- Nausea (rare)
- Headache (rare)
- Dizziness (rare)
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- +4 more
- Stacks With
- —
- —